Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Opus Genetics, Inc.NASDAQ: IRD
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $1K a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 2K | -86.7% |
| FY2023 | 2023-12-31 | 15K | -69.4% |
| FY2022 | 2022-12-31 | 49K | -77.6% |
| FY2021 | 2021-12-31 | 219K | — |
Short-term Investments vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 short-term investments of $0 is the 6th highest of the 10 companies compared; the peer median is $11.41M.
- Its year-over-year change of -100.0% is the lowest of 6, against a peer median of -36.3%.
- Short-term investments amounts to 0.0% of total assets for IRD, versus a peer median of 22.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $129.55M | -59.1% | -30.2% | 54.0% | |
| Mar 2026 | $119.35M | -36.3% | -27.8% | 43.9% | |
| Mar 2026 | $76.6M | -35.6% | +9.8% | 57.3% | |
| Mar 2026 | $69.55M | -21.2% | -31.6% | 34.7% | |
| Mar 2026 | $11.41M | -59.9% | -59.0% | 22.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IRD) | $11.41M | -36.3% | -30.2% | 22.9% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.